Amgen Inc (AMGN) 134.79 $AMGN
'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - 31 mins ago
The trading panel looked at banks and the top buy and sell candidates for right now.
Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 5:25PM CDT
The EMA accepted Cubist Pharmaceuticals' (CBST) MAA for its investigational antibiotic, ceftolozane/tazobactam.
Final Glance: Biotechnology companies
AP - Mon Aug 25, 5:24PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Amgen Set to Possibly Pullback After Yesterday's Rally of 1.48%
Comtex SmarTrend(R) - Mon Aug 25, 3:53PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $133.38 to a high of $134.93. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $133.46 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.48% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 3:53PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $133.38 to a high of $134.93. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $133.46 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier Leonetti Of Amgen And Formerly At Dell
PR Newswire - Mon Aug 25, 3:15PM CDT
Western Digital Corp. (NASDAQ: WDC) today announced that chief financial officer Tim Leyden, 62, is retiring after 24 years of distinguished service at the company. He is being succeeded by Olivier Leonetti, 50, who has served as vice president, finance at Amgen Inc. from 2011, after having previously spent 14 years in global finance leadership positions at Dell Inc. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8, 2014.
Early Glance: Biotechnology companies
AP - Mon Aug 25, 9:37AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Kindred Biosciences Falls on Disappointing CereKin Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 8:22AM CDT
Shares of Kindred Biosciences, Inc. (KIN) plunged 28.2% as a pivotal field study on its pipeline candidate CereKin (interleukin-1 inhibitor) failed to meet the primary endpoint.
Eli Lilly Uncovers Positive Data from Ixekizumab Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:45PM CDT
Eli Lilly and Company (LLY) announced encouraging results from three studies under theUNCOVER program on ixekizumab.
Amgen Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:40PM CDT
On Aug 21, Zacks Investment Research upgraded Amgen Inc. (AMGN) to a Zacks Rank #1 (Strong Buy).
Midday Glance: Biotechnology companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Biosimilars and Biobetters experts share their opinion on the market in a series of interviews: Harvest Moon, Medimmune, Amgen, Interpham Consultancy
PRWeb - Fri Aug 22, 7:46AM CDT
As the global market for biosimilars gets set to rapidly expand by more than 20-fold in the next five years, analysis suggests that the market will rise from just $1.2bn last year to $23bn in 2019 (based on the analysis by Frost & Sullivan). With this is mind SMi asked their key speakers for Biosimilars & Biobetters-2014 the following questions: How will the entry of originator companies entering the industry really impact on the biosimilars industry? How are the current regulatory standards affecting Europe? As the ongoing debate regarding 'naming' continues, how is this impacting the industry? In your opinion, what do doctors think of biosimilars and how willing are they to prescribe them? What do you think biosimilars mean to the patient, or do they even know the difference? To read the interviews with these industry leaders please go to http://www.smi-online.co.uk/pharmaceuticals/u...=downloads Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals Rakesh Dixit, VP, R&D, Global Head, Biologics Safety Assessment, Medimmune (AstraZeneca Biologics) Catherine Akers, Regulatory Affairs Manager, Amgen Peter Wittner, Senior Consultant, Interpharm Consultancy Returning for its fifth year and following on from the major success of previous events, SMI are proud to present the 5th annual Biosimilars & Biobetters Conference, 29th-30th September, 2014, London. With an in-depth focus on the current and future landscape of the biosimilars market, this meeting will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.
The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report).
Lilly psoriasis drug fares well in late-stage test
AP - Thu Aug 21, 7:55AM CDT
INDIANAPOLIS (AP) — Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.
3 Reasons Gilead Science, Inc.’s Stock Could Rise
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 20, 4:36PM CDT
Gilead Sciences is trading near all-time highs, but there's still potential for the stock price to go even higher. Here are three things that could send shares higher if they come to fruition. Source: Gilead. 1. Sales of Gilead's...
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - 31 mins ago
The trading panel looked at banks and the top buy and sell candidates for right now.
Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 5:25PM CDT
The EMA accepted Cubist Pharmaceuticals' (CBST) MAA for its investigational antibiotic, ceftolozane/tazobactam.
Final Glance: Biotechnology companies
AP - Mon Aug 25, 5:24PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Amgen Set to Possibly Pullback After Yesterday's Rally of 1.48%
Comtex SmarTrend(R) - Mon Aug 25, 3:53PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $133.38 to a high of $134.93. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $133.46 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.48% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 3:53PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $133.38 to a high of $134.93. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $133.46 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier Leonetti Of Amgen And Formerly At Dell
PR Newswire - Mon Aug 25, 3:15PM CDT
Western Digital Corp. (NASDAQ: WDC) today announced that chief financial officer Tim Leyden, 62, is retiring after 24 years of distinguished service at the company. He is being succeeded by Olivier Leonetti, 50, who has served as vice president, finance at Amgen Inc. from 2011, after having previously spent 14 years in global finance leadership positions at Dell Inc. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8, 2014.
Early Glance: Biotechnology companies
AP - Mon Aug 25, 9:37AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Kindred Biosciences Falls on Disappointing CereKin Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 8:22AM CDT
Shares of Kindred Biosciences, Inc. (KIN) plunged 28.2% as a pivotal field study on its pipeline candidate CereKin (interleukin-1 inhibitor) failed to meet the primary endpoint.
Eli Lilly Uncovers Positive Data from Ixekizumab Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:45PM CDT
Eli Lilly and Company (LLY) announced encouraging results from three studies under theUNCOVER program on ixekizumab.
Amgen Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:40PM CDT
On Aug 21, Zacks Investment Research upgraded Amgen Inc. (AMGN) to a Zacks Rank #1 (Strong Buy).
Midday Glance: Biotechnology companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Biosimilars and Biobetters experts share their opinion on the market in a series of interviews: Harvest Moon, Medimmune, Amgen, Interpham Consultancy
PRWeb - Fri Aug 22, 7:46AM CDT
As the global market for biosimilars gets set to rapidly expand by more than 20-fold in the next five years, analysis suggests that the market will rise from just $1.2bn last year to $23bn in 2019 (based on the analysis by Frost & Sullivan). With this is mind SMi asked their key speakers for Biosimilars & Biobetters-2014 the following questions: How will the entry of originator companies entering the industry really impact on the biosimilars industry? How are the current regulatory standards affecting Europe? As the ongoing debate regarding 'naming' continues, how is this impacting the industry? In your opinion, what do doctors think of biosimilars and how willing are they to prescribe them? What do you think biosimilars mean to the patient, or do they even know the difference? To read the interviews with these industry leaders please go to http://www.smi-online.co.uk/pharmaceuticals/u...=downloads Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals Rakesh Dixit, VP, R&D, Global Head, Biologics Safety Assessment, Medimmune (AstraZeneca Biologics) Catherine Akers, Regulatory Affairs Manager, Amgen Peter Wittner, Senior Consultant, Interpharm Consultancy Returning for its fifth year and following on from the major success of previous events, SMI are proud to present the 5th annual Biosimilars & Biobetters Conference, 29th-30th September, 2014, London. With an in-depth focus on the current and future landscape of the biosimilars market, this meeting will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.
The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report).
Lilly psoriasis drug fares well in late-stage test
AP - Thu Aug 21, 7:55AM CDT
INDIANAPOLIS (AP) — Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.
3 Reasons Gilead Science, Inc.’s Stock Could Rise
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 20, 4:36PM CDT
Gilead Sciences is trading near all-time highs, but there's still potential for the stock price to go even higher. Here are three things that could send shares higher if they come to fruition. Source: Gilead. 1. Sales of Gilead's...
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
